BEAT:NSD-BioTelemetry, Inc (USD)

COMMON STOCK | Health Information Services | NSD

Last Closing Price

USD 0.00

Change

0.00 (0.00)%

Market Cap

USD 2.47B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

HeartBeam, Inc., a medical technology company, primarily focusing on telemedicine solutions that enable the detection and monitoring of cardiac disease. It focuses on providing diagnostic data to help physicians with care management of patients with cardiovascular disease. The company is developing its telehealth product that comprises a credit card sized electrocardiograms machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is based in Santa Clara, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-27 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CERN Cerner Corporation

-2.06 (-2.86%)

USD21.27B 31.49 13.27
TXG 10x Genomics Inc

-6.69 (-4.04%)

USD18.37B N/A N/A
GDRX GoodRx Holdings Inc

-1.93 (-4.35%)

USD17.96B 927.27 238.21
OMCL Omnicell Inc

-2.72 (-1.59%)

USD7.42B 128.97 45.65
CHNG Change Healthcare Inc

-0.18 (-0.84%)

USD6.64B N/A 14.58
INOV Inovalon Holdings Inc

-0.03 (-0.07%)

USD6.33B 153.89 34.32
RCM R1 RCM Inc

-0.54 (-2.48%)

USD6.12B 72.63 31.09
HQY HealthEquity Inc

-2.23 (-3.28%)

USD5.68B 7,551.11 42.11
PGNY Progyny Inc

-2.04 (-3.27%)

USD5.58B 80.15 178.95
PINC Premier Inc

-0.83 (-2.12%)

USD4.80B 17.61 13.98

ETFs Containing BEAT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Health Information Services)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 22.54% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.54% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 45.10% N/A N/A N/A N/A
Risk Adjusted Return 49.97% N/A N/A N/A N/A
Market Capitalization 2.47B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Health Information Services)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 149.92 N/A N/A N/A N/A
Price/Book Ratio 6.25 N/A N/A N/A N/A
Price / Cash Flow Ratio 36.55 N/A N/A N/A N/A
EV/EBITDA 30.62 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 4.67% N/A N/A N/A N/A
Return on Invested Capital 14.88% N/A N/A N/A N/A
Return on Assets 4.71% N/A N/A N/A N/A
Debt to Equity Ratio 52.01% N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.20 N/A N/A N/A N/A
Short Percent 5.11% N/A N/A N/A N/A
Beta 1.31 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike